| Project/Area Number |
09671253
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
TOKUDA Yutaka TOKAI UNIVERSITY, SCHOOL OF MED., ASSOCIATE PROFESSOR, 医学部, 助教授 (20163975)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UEYAMA Yoshito TOKAI UNIVERSITY, SCHOOL OF MED., ASSOCIATE PROFESSOR, 医学部, 助教授 (30072408)
SHIMAMURA.KASUO TOKAI UNIVERSITY, SCHOOL OF MED., ASSOCIATE PROFESSOR, 医学部, 助教授 (00119679)
|
|---|
| Project Period (FY) |
1997 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,200,000 (Direct Cost: ¥3,200,000)
Fiscal Year 1999: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1998: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1997: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | C-erbB-2 / Humanized monoclonal antibody / Anticancer drugs / SCID mice |
|---|
| Research Abstract |
The c-erbB-2 product is thought to be an unique and useful target for antibody therapy of cancers overexpressing the c-erbB-2 gene. A humanized antibody which contained only the antigen-binding loops from a murine monoclonal antibody against the extracellular domain of the c-erbB-2 gene product, human variable region framework residues and IgG1 constant domains was constructed.
In vivo anti-tumor effects of the humanized anti-c-erbB-2 monoclonal antibody with CDDP were examined using SCID mice bearing 4-1ST and St-40 of c-erbB-2 positive human gastric cancer xenografis. Anti-tumor effects of the antibody were found to be synergistic with CDDP. The precise underlying mechanism for this synergistic interaction remains unknown, though it is currently being evaluated. Preliminary, platinum contents of the tumors were higher in the mice treated with CDDP and the antibody than those only with CDDP. These synergistic or additive effects were also found in the mice treated with etoposide and MMC in conjunction with the antibody.
|
